US OptionsDetailed Quotes

SVRA241220C2000

Watchlist

0.00
0.000.00%

15min DelayTrading Dec 16 09:30 ET

0.00High0.00Low

Savara Stock Discussion

Jaguar8

Dec 1 01:14

🔵Watchlist Monday December 2. NFA. Trade the Chart. No emotions. No FOMO

NOTE:
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
4. If you are expecting all stocks to be a runner,then you are set for failure, losses, and bagholding. Not all good news run and not all bad news crash the pri...

Trytosaveabit

Nov 22 07:08

Watching

$Savara (SVRA.US)$ Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...

Jaguar8

Nov 22 07:07

NEWS

$Savara (SVRA.US)$
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara announced an encore presentation of Phase 3 IMPALA-2 trialresults for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meet...

Teddy123

Nov 12 07:26

In the pipeline

$Savara (SVRA.US)$
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...

NEWS

$Savara (SVRA.US)$
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Savara Inc. (Nasdaq: SVRA) announced that a new episode of The Balancing Act® on Lifetime TV's Behind the Mystery™ series is featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP). The episode, sponsored by Savara, focuses on an aPAP patient's diagnostic journey and includes insights from Dr. Bruce Trapn...

Clintzilla

Sep 27 17:23

$Savara (SVRA.US)$ Phase 3 update will be presented Monday.. keep watch

Jaguar8

Sep 27 07:12

Plans to Complete Submission of a Bla to FDA for Molgramostim in Apap in H1 of 2025

$Savara (SVRA.US)$

Trytosaveabit

Sep 27 07:07

Update

$Savara (SVRA.US)$ Reuters· just
Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)

Jaguar8

Sep 27 07:05

NEWS

$Savara (SVRA.US)$
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) has announced the Savara Early Access Program, an Expanded Access Program (EAP) for molgramostim inhalation solution to treat patients with autoimmune pulmonary alveolar proteinosis (aPAP). This program allows physicians to request molgramostim for eligible aPAP patients in select re...

No comment yet